摘要
本文研究了罗伊氏乳杆菌CCFM8631对高脂饮食诱导的高血脂症小鼠的降脂作用.将小鼠随机分为对照组(CK)、高血脂症模型组(HFD)和L.reuteri CCFM8631组(CCFM8631).在成功建立高脂模型后,持续给药28 d,随后,对小鼠的体重和脏器指数进行了测定,并检测血清中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋(LDL-C)、高密度脂蛋白(HDL-C)等指标,以及肝脏损伤、炎症因子和血管功能的生化指标.实验结果表明,与HFD组相比,CCFM8631组小鼠的体重、肝脏指数和脂肪指数均显著下降.CCFM8631组小鼠血清中TC、TG、LDL-C含量显著下降,HDL-C显著上升.CCFM8631组小鼠的肝脏损伤、炎症因子和血管功能均得到缓解和改善.上述结果表明,CCFM8631可以作为一种潜在降血脂的功能性膳食补充剂,用于预防和治疗高血脂症.
Abstract
In this study,the hypolidemic effects of Lactobacillus reuteri CCFM8631 in mice with hyperlipidemia induced by a high-fat diet was investigated. Mice were randomly assigned to three groups:a control group (CK),a hyperlipidemic model group (HFD),and a Lactobacillus reuteri CCFM8631 group (CCFM8631). Following the successful establishment of the hyperlipidemic model,treatment continued for 28 days,body weight,organ indices,and serum levels of various parameters including total cholesterol (TC),triglycerides (TG),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C),liver injury biomarker,inflammatory factors and vascular function were assessed. Results indicated that,compared to the HFD group,mice in the CCFM8631 treatment group showed significant reductions in body weight,liver index,and fat index. Additionally,serum TC,TG,LDL-C levels were significantly decreased,while HDL-C levels significantly elevated in the CCFM8631 group. Moreover,liver injury,inflammatory factors and vascular function were improved in the CCFM8631 treatment group. These findings suggested that Lactobacillus reuteri CCFM8631 had the potential to serve as a lipid-lowering functional dietary supplement for the prevention and treatment of hyperlipidemia.
国家科技期刊平台
NSTL
万方数据